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Abstract
Background: Collection of exhaled breath samples for the analysis of inflammatory biomarkers is an important area of
research aimed at improving our ability to diagnose, treat and understand the mechanisms of chronic pulmonary disease.
Current collection methods based on condensation of water vapor from exhaled breath yield biomarker levels at or near the
detection limits of immunoassays contributing to problems with reproducibility and validity of biomarker measurements. In
this study, we compare the collection efficiency of two aerosol-to-liquid sampling devices to a filter-based collection
method for recovery of dilute laboratory generated aerosols of human cytokines so as to identify potential alternatives to
exhaled breath condensate collection.
Methodology/Principal Findings: Two aerosol-to-liquid sampling devices, the SKCH Biosampler and Omni 3000
TM, as well
as TeflonH filters were used to collect aerosols of human cytokines generated using a HEART nebulizer and single-pass
aerosol chamber setup in order to compare the collection efficiencies of these sampling methods. Additionally, methods for
the use of TeflonH filters to collect and measure cytokines recovered from aerosols were developed and evaluated through
use of a high-sensitivity multiplex immunoassay. Our results show successful collection of cytokines from pg/m
3 aerosol
concentrations using TeflonH filters and measurement of cytokine levels in the sub-picogram/mL concentration range using
a multiplex immunoassay with sampling times less than 30 minutes. Significant degradation of cytokines was observed due
to storage of cytokines in concentrated filter extract solutions as compared to storage of dry filters.
Conclusions: Use of filter collection methods resulted in significantly higher efficiency of collection than the two aerosol-to-
liquid samplers evaluated in our study. The results of this study provide the foundation for a potential new technique to
evaluate biomarkers of inflammation in exhaled breath samples.
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Introduction
Chronic respiratory diseases such as asthma, chronic obstructive
pulmonary disease (COPD), and lung cancer affect hundreds of
millions of people worldwide and cause over four million deaths
annually [1]. Although many risk factors have been identified for
both asthma and COPD, a complete understanding of the
underlying disease mechanisms has not yet been achieved for
either chronic disease. Additionally, improvements in tools used
for diagnosing and managing these diseases are urgently needed
[2,3,4].
Exhaled breath is an aerosol consisting mostly of water vapor,
with smaller amounts of volatile, semi-volatile, and non-volatile
molecules derived from the upper and lower portions of the
respiratory system [5,6]. Cytokines are small, water-soluble
signaling proteins produced by cells of the immune system to
modulate responses of the immune system such as inflammation.
Since inflammation is an underlying condition of many chronic
diseases, exhaled cytokines can be considered biomarkers of
pulmonary inflammation that could indicate the presence of lung
diseases or provide information regarding the current status of the
lungs. Non-invasive monitoring of lung inflammation through
detection and measurement of cytokines in exhaled breath samples
is a promising new approach aimed at addressing the need for
improved understanding, treatment and management of chronic
respiratory diseases such as asthma and COPD.
Over the last 15 years, there has been increasing interest in the
development and use of exhaled breath condensate (EBC)
techniques for the collection and analysis of aerosolized droplets
of respiratory lining fluid (RLF). Collection of EBC samples is a
non-invasive and relatively well-tolerated procedure accomplished
through simple means whereby a subject breathes normally into a
chilled collection device that condenses and collects the fluid
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components [6]. The most abundant component (99%) of EBC
samples is liquid water formed from the condensation of water
vapor present in the warm exhaled air, saturated with water vapor
as it leaves the respiratory tract. The second and third components
of EBC samples are water-soluble volatiles and non-volatile
particles that are aerosolized from the respiratory lining fluid
and are present in significantly smaller amounts than the water
component of EBC samples [6,7,8,9,10,11]. The significant
amount of liquid water present in EBC samples dilutes the
inherently low concentrations of non-volatile biomarkers to levels
that are at or below the detection threshold of most commercially
available assays [6]. The inefficient collection of exhaled,
nonvolatile submicron particles using EBC methods combined
with assay sensitivity limitations creates significant problems with
reproducibility and validity of biomarker measurements [6,10,11,
12,13,14]. Several recent papers suggest that collection of
respiratory particles by more efficient methods may be feasible
and avoid some of the problems with EBC including variable
collection efficiency with variable tidal flow [15,16,17,18].
Since exhaled breath is a bioaerosol and liquid-based collection
methods may preserve biological function of protein biomarkers,
aerosol-to-liquid based sampling devices might be useful for
collection of exhaled breath samples. Liquid-impinger sampling
devices collect aerosolized particles into a liquid medium through
inertial impaction. The use of liquid collection medium prevents
desiccation and possible degradation of collected particles,
however, the forces used for liquid-impingement collection can
be destructive to biological molecules [19]. One well-known and
frequently used liquid-impingement aerosol sampler, the BioSam-
plerH (SKC Inc., Eighty Four, PA), utilizes centrifugal forces for
more gentle collection of particles and is widely recognized for its
ability to preserve biological function. However, key disadvantages
associated with the BioSamplerH include its relatively low sample
flow rate and high sample collection volume which results in
considerable dilution of collected particles. Another technology
offering the benefits of liquid-based sample collection is the wetted-
wall cyclone. In this method, aerosolized particles are subjected to
centrifugal forces whereby particles are deposited onto the wetted
wall of the sampling device due to inertial forces. Since this device
utilizes a relatively high sample flow rate combined with a
relatively low sample collection volume, it may offer improved
collection over liquid-impingement collection devices. However,
the suitability of this collection method to aerosolized non-volatile
particles such as cytokines has not yet been established or
compared to liquid-impingement aerosol collectors.
Filters collect particles through a variety of mechanisms. Direct
interception and impaction favor larger particles, while diffusion
and electrostatic forces favor small submicron particles. Thus,
filters are capable of collecting a wide range of particle sizes.
Impingers and cyclones favor collection of large particles and
typically have low collection efficiencies for submicron particles
[19,20]. Given that a number of recent studies have consistently
demonstrated that the majority of exhaled breath particles are in
the submicron (,1 mm) range [21,22,23], the use of filters for
collection of exhaled breath samples may offer a promising new
efficient means for collection of non-volatile cytokines. Recent
work has successfully demonstrated the ability to collect influenza
particles from aerosols generated with a nebulizer and one-pass
aerosol chamber [24] and from exhaled human breath samples
using TeflonH filters [17]. Additionally, successful collection and
analysis of exhaled breath biomarkers has been demonstrated
using silicon plates and Time-of-Flight Secondary Ion Mass
Spectrometry (TOF-SIMS) [25] and ELISA [15,16]. These studies
suggested that collection and measurement of human cytokine
aerosols generated in a similar manner might be possible using
filter-based methods and may be much more efficient at recovery
of respiratory fluid biomarkers than condensate [15].
In this paper, we report the sampling and detection of human
cytokine aerosol generated using a nebulizer and transported
through a single-pass aerosol chamber. A high volume chamber
flow was used to dilute the cytokine aerosol to more realistic levels.
We examine the collection efficiency for human cytokine aerosols
of TeflonH filters and two aerosol-to-liquid samplers: the
BiosamplerH and the Omni 3000
TM. We also report results of
sampling a range of aerosolized cytokine concentrations for the
purpose of generating filter samples containing cytokine levels
below, near and above the detection limits of a high-sensitivity
multiplex immunoassay. With this data, we assess the variability of
collection and assay methods at low cytokine levels likely to be
encountered in human exhaled breath studies. Finally we evaluate
the effect of storage conditions, such as would be required by most
clinical or epidemiologic field studies, on degradation of cytokines
collected with TeflonH filters.
Methods developed and optimized as a result of this study may
be used to evaluate the feasibility of filter-based collection methods
to collect and measure human cytokines in exhaled breath samples
and offer a novel method for monitoring pulmonary biomarkers of
inflammation.
Results
Experiment 1: Estimation of Aerosolized Cytokine
Concentrations and Comparison of Aerosol Sampler
Collection Efficiency
Estimated aerosol concentrations in the single pass aerosol
chamber for all cytokines, based on measurements of cytokines
in the nebulizer before and after each run, were typically in the
20–40 pg/m
3 range with notable cytokine-dependent variability
(Figure 1).
All measured cytokine levels in Experiment 1 were above the
lowest standard of the assay (0.03 pg/mL). Variability of cytokine
level measurements was high for all cytokines and sampling
devices (Figure 2). Overall collection efficiency was poor (,20%)
Figure 1. Estimated airborne concentrations of six human
cytokines produced in single-pass aerosol chamber. Data shown
for estimated expected airborne concentrations (pg/m
3 air) of six
different human cytokines as calculated by Equation 1 (N=2; 95% CI).
doi:10.1371/journal.pone.0035814.g001
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Omni-3000
TM and filters concentrated using rotary centrifugal
evaporation (Figures 2, 3). For all cytokines tested, filter collection
yielded higher collection efficiencies than either the Omni 3000
TM
or SKC BiosamplerH (Figures 2, 3). IL-7 seemed to be particularly
difficult to recover using the SKC BiosamplerH while IFN-gamma
was difficult to recover using the Omni-3000 (Figure 2). Significant
differences in mean collection efficiencies of all six cytokines
among the three samplers were observed (Figure 3, Kruskal-Wallis
ANOVA, P,0.05). Subsequent paired student’s t-tests indicated
significantly improved mean collection efficiency using filters as
compared with mean collection efficiencies of either the Omni
TM-
3000 (P,0.0001) or BiosamplerH (P=0.01), Figure 3). No
significant difference in mean collection efficiency was observed
between the Omni 3000
TM and BiosamplerH (P=0.64, Figure 3).
The coefficient of variation (CV) calculated for cytokine measure-
ments on samples collected from filters and concentrated using
rotary evaporation, BiosamplerH and Omni 3000
TM were 37%,
55% and 68%, respectively.
Experiment 2: Cytokine Stability, Use of Filter
Centrifugation Concentration and Effect of
Sampling Time and Cytokine Concentrations on Assay
Repeatability
Degradation of cytokines in solution at 25 pg/mL was found to
be insignificant over 30 minutes of nebulization at 68.9 kPa
(Kruskal-Wallis ANOVA, P.0.05, Figure S1).
Spike-recovery experiments evaluating the use of Amicon Ultra-
4 3000 MWCO centrifugal filter concentrators indicated approx-
imately 80% sample recovery as compared to approximately 50%
recovery of sample using rotary centrifugal evaporation methods.
Passivation of centrifugal filter concentrators did not result in
significantly higher recovery of cytokines as compared to untreated
filters (student’s t-test, P.0.05).
Filter samples collected from aerosolization of cytokines at
25 pg/mL and concentrated using centrifugal filter concentrators
displayed significantly improved collection efficiency as compared
to filter samples collected and concentrated using rotary centrif-
ugal evaporation (Figure 3, t-test, P=0.003). Mean collection
efficiency of filter extracts concentrated using centrifugal filter
concentrators was approximately twice that of filter extracts
concentrated using rotary evaporation (Figure 3, 26% versus 13%)
and nearly 5-fold higher than the collection efficiency of the
Omni-3000
TM (5.6%) and the BiosamplerH (4.8%). As in
Experiment 1, cytokine-specific differences in collection efficiency
were observed when using the centrifugal filter concentrators
(Figure 2). Additionally, the CV of filter sample extracts
concentrated using centrifugal filter concentrators was lower than
that of extracts concentrated with rotary evaporation (21% versus
37%).
Filter samples were collected from aerosolized human cytokines
that yielded measured cytokine levels below, near 10-fold and 100-
fold above the assay manufacturer’s reported MinDC of the high-
sensitivity multiplex immunoassay (Figure 4). All cytokine levels
measured from filters collected from aerosolization of cytokines at
25 pg/mL were above the lowest standard of the assay (0.03 pg/
mL; observed range 0.7 pg/mL to 39.7 pg/mL). Three sample
cytokine level measurements (2%) from filters taken from
aerosolization of cytokines at 10 pg/mL (observed range 0.2 pg/
mL to 13 pg/mL) and 35 cytokine level measurements (26%) from
filters taken from aerosolization of cytokines at 1 pg/mL displayed
levels below the lowest standard of the assay (0.03 pg/mL;
observed range 0.03 pg/mL to 4.4 pg/mL). Significant increases
in cytokine collection corresponded with increased starting
concentration and increased sampling time (Figure 4, Kruskal-
Wallis ANOVA, P,0.05). Additionally, repeatability of measure-
ments increased with increasing cytokine concentrations as
indicated by 95% CI bars (Figure 4).
Figure 2. Comparison of sampling device collection efficiencies by cytokine. Collection efficiencies calculated using Equation 3 for each of
six different human cytokines using different collection devices in a single-pass aerosol chamber (N=6; 3 filters assayed in duplicate, 95% CI).
doi:10.1371/journal.pone.0035814.g002
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observed among the six cytokines tested in the study. (Figures
S2, S3, S4, S5, S6, S7, Kruskal-Wallis ANOVA, P,0.05).
However, the trends were the same for all cytokines tested. Each
cytokine displayed significant increases in collected amount at
increased starting concentrations and sampling times (Figures S2,
S3, S4, S5, S6, S7, Kruskal-Wallis ANOVA, P,0.05).
Repeatability of measurements, measured as a reduction in CV,
was improved by increasing starting concentrations. However,
longer sampling times did not appear to significantly improve
repeatability of measurements.
Blank filter samples that received no air exposure contained no
detectable levels of cytokines.
Experiment 3: Effect of Storage Conditions
All measured cytokine levels were above the lowest standard of
the assay (0.03 pg/mL). Mean cytokine levels of thirteen different
cytokines varied significantly with storage condition (Figure 5,
Kruskal-Wallis ANOVA, P,0.001). Comparisons made using
student’s t-tests of individual pairs of storage conditions showed no
significant difference between samples receiving no storage
(control condition) and filter samples stored at either 220uCo r
280uC. However, significant decreases in cytokine levels were
observed for concentrated samples stored at either 220uCo r
280uC when compared to samples receiving no storage
(P#0.0005) or when compared to filter samples stored at 220uC
(P,0.05) or filter samples stored at 280uC( P ,0.01). No
significant difference was observed between concentrate samples
stored at 220uCo r280uC (P=0.20).
Individual analyses of thirteen cytokines revealed similar
responses to storage conditions (Figures S8, S9, S10, S11, S12,
S13, S14, S15, S16, S17, S18, S19, S20), with increased
degradation of cytokines observed in concentrate samples stored
at both 220uC and 280uC. Total amounts of GM-CSF, IFN-
gamma, IL-1 beta, IL-2, IL-4, IL-5, IL-7, IL-8, varied significantly
with storage condition (Kruskal-Wallis ANOVA, P,0.05). Total
amounts of IL-6 displayed borderline significant differences across
storage conditions (Kruskal-Wallis ANOVA, P=0.06).
Blank filter samples that received no air exposure contained no
detectable levels of cytokines.
Discussion
The diagnosis and treatment of pulmonary diseases would
benefit greatly from a sensitive, non-invasive method of identifi-
cation and measurement of biomarkers of pulmonary inflamma-
tion creating much interest in the collection of exhaled breath
particles for measurement of cytokines. A number of recent studies
have shown a predominance of exhaled breath particles in the
submicron range [21,22,23]. Collection of exhaled breath particles
through condensation using EBC techniques or through the use of
Figure 4. Effect of sampling time and initial starting concentration on cytokine collection. Mean cytokine levels (pg) of six human
cytokines collected using Teflon filters in aerosol chamber for 10, 20 and 30 minutes at starting concentrations of 1, 10 and 25 pg/mL. 95% CI bars are
shown (N=48, 4 filters assayed in duplicate for each of 6 cytokines).
doi:10.1371/journal.pone.0035814.g004
Figure 3. Comparison of mean collection efficiencies by
sampling device type. Tukey Box Plot of mean collection efficiencies
calculated using Equation 3 of six human cytokines using different
collection devices in a single-pass aerosol chamber (N=36; 3 filters
assayed in duplicate for each of 6 different cytokines, 95% CI).
* indicates significance at P,0.05.
doi:10.1371/journal.pone.0035814.g003
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and Omni 3000
TM are not very efficient collectors of submicron
particles [20]. Based on aerosol theory, filters are expected to
outperform these collections systems for particles in the submicron
range and offer the potential for development of novel exhaled
breath collection systems and methodologies.
Our results indicate that collection of aerosolized human
cytokines is feasible using TeflonH filters at airborne concentra-
tions in the pg/m
3 air range. The ability of this filter-based method
to capture and detect human cytokines at such low concentrations
suggests the possibility of utilizing this technique for collection and
measurement of cytokines in exhaled breath samples. The use of
TeflonH filters improved the collection of human cytokine aerosols
by approximately 5-fold as compared to traditional aerosol-to-
liquid-samplers such as the BiosamplerH and Omni-3000
TM
(Figures 2 and 3). Additionally, variability of cytokine measure-
ments for both the BiosamplerH and Omni-3000
TM were much
higher than that of filter-based collection when extracts were
concentrated using centrifugal filter concentration (55% and 68%,
respectively versus 21%). Differences in collection efficiency may
be explained by decreased ability of the aerosol-to-liquid samplers
to capture submicron particles. A recent review article cited a
study that estimated liquid-based sampling devices lose as much as
90% of submicron particles [20]. However, individual collection
efficiencies will vary based on sampler design and operating
parameters. Increased variability observed in the liquid-sampling
methods may also be due to decreased collection efficiencies that
produced lowered measurable concentrations of cytokines that
were closer to the sensitivity limits of the immunoassay. Increased
efficiency and decreased variability of collection of non-volatile
biomarkers through the use of filter-based collection methods
could increase the amount of cytokine available for subsequent
detection and quantitative assays. These improvements may help
address the reproducibility and validity problems encountered in
exhaled breath condensate methods due to measurement of
biomarkers at concentrations near assay detection limits
[12,13,14].
Our study suggests that cytokines can be detected from aerosols
at levels near the MinDC of the high-sensitivity multiplex
immunoassay (Figure 4, Figures S2, S3, S4, S5, S6, S7). This
represents the potential to detect cytokines in the sub-picogram/
mL range from aerosols containing cytokines in the picogram/m
3
range with sampling times of 30 minutes or less (Figures 1 and 5,
Figures S2, S3, S4, S5, S6, S7). Detection of cytokines at this level
of sensitivity is of importance since the content of exhaled breath
samples has been estimated to contain 99.99% water vapor with
non-volatile molecules comprising ,0.01% of exhaled breath
condensate samples [8]. Higher variability of cytokine measure-
ments made at the lower cytokine concentrations (Figure 4,
Figures S2, S3, S4, S5, S6, S7) may not likely be useful for
quantitative purposes, but may be within an acceptable range for
detecting significant differences in cytokine concentrations among
individuals or determining the presence or absence of various
cytokines in various samples.
In this study we evaluated four different storage conditions that
were selected based on the most likely workflow that would be
implemented in sample processing protocols. Results of this study
indicate that storage conditions should be evaluated for each
cytokine in a study when developing a cytokine measurement
assay method. Our study displayed significantly decreased levels of
cytokine for those samples stored as concentrated filter extracts at
220uCo r280uC (Figure 5, Figures S8, S9, S10, S11, S12, S13,
S14, S15, S16, S17, S18, S19, S20). Additionally, results of our
study show that cytokines vary significantly in their susceptibility to
degradation during storage (Figures S8, S9, S10, S11, S12, S13,
S14, S15, S16, S17, S18, S19, S20). Other studies have also shown
the importance of handling and storage of cytokine samples and
demonstrated differences in susceptibility among cytokines
[26,27,28]. Potential causes for the observed differences in stability
were speculated to be cytokine tertiary or quaternary structural
variations or components of the sample matrix [28]. Our results
also suggest a significant decrease in recovered cytokine amounts
when storing samples as concentrated filter extracts at either
220uCo r280uC versus filters stored at 220uCo r280uCo r
samples receiving no storage (Figure 5). However, due to
variability in assay measurements, further study is warranted to
confirm the validity of this finding. A recent study by Weist (2010)
evaluating protein storage and handling conditions concluded that
tissue samples could be stored at 280uC for years without
significant degradation, but extracts frozen at 280uC and thawed
showed significant degradation [29]. Our study concurs with the
results of Weist’s study indicating significantly higher degradation
of stored extracts as compared to filter samples stored at the same
temperature. Potential causes for this decrease could be due to
degradation of proteins in the presence of water and oxygen or loss
of sample to the storage tube.
A limitation of our study was use of optimized, experimental
conditions with an artificial aerosol diluted in a large air flow to
simulate concentrations that might be encountered in exhaled
breath. We did not match the temperature and humidity of
exhaled breath in this system. The constant air flow in our
sampling devices differed from cyclically variable flow in EBC
devices, but was similar to that in more recent exhaled breath
sampling devices used by our lab and others [15,16,17,18]. We
used BSA to mimic the concentration of proteins in respiratory
lining fluids and used Tween-20 as a surfactant rather than trying
to match the mixture of proteins and surfactant proteins and lipids
present in the distal airways. Thus, these artificial conditions can
only explore the feasibility of new collection methods as
alternatives to currently popular EBC methods. Future studies to
explore the utility of this method for collection of exhaled breath
Figure 5. Effect of storage condition on mean cytokine levels.
Mean cytokine levels (pg) across five different storage conditions (95%
CI, N=156, 6 filters assayed in duplicate for each of 13 human
cytokines). * indicates statistically significant difference from No Storage
control condition (Kruskal-Wallis ANOVA, P,0.05).
doi:10.1371/journal.pone.0035814.g005
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can be more widely adopted for research.
Another limitation of our study was the small number of
sampler types evaluated for the collection of non-volatile particles
from bioaerosols. Other types of samplers exist and should be
evaluated; e.g. Mainelis (2002) demonstrated efficient collection
bioaerosols while preserving biological function through the use of
an electrostatic precipitator collection device [30]. In contrast to
bioaerosol impactors and impingers, electrostatic precipitators
offer the ability to collect samples in a liquid medium at particle
velocities 2–4 orders of magnitude lower than impactors and
impingers and thus offer the ability to collect particles in a manner
that may aid in preserving biological function. Additionally, Han
and Mainelis (2010) have shown the ability to use an electrostatic
precipitator with superhydrophobic collection surface (EPSS) to
collect bioaerosol samples into concentrated volumes to allow for
detection of molecules present at very low concentrations [31].
These studies provide another feasible approach for collection of
aerosolized human cytokines at low concentrations while preserv-
ing biological activity that could be evaluated in future work. A
newer technology recently reviewed by Adler (2008) combining
immunoassay with nucleic acid amplification allows for detection
of biological molecules at concentrations as low as 1 femtogram/
mL offering a 100–1000X increase in sensitivity over current
methods [32]. Application of this new technology to measurement
of cytokines in exhaled breath samples may provide the assay
sensitivity and reproducibility needed for cytokine profiling in
chronic pulmonary disease and warrants further study.
Conclusions
Our study demonstrated successful collection of aerosolized
human cytokines in the pg/m
3 concentration range using filter
based methods and measurement of cytokine levels in the sub-
picogram/mL range using a high-sensitivity multiplex immuno-
assay utilizing sampling times of 10 to 30 minutes. Use of TeflonH
filters yielded significant improvements in collection of aerosolized
human cytokines as compared to two standard aerosol-to-liquid-
collection methods. This finding suggests a new method of exhaled
particle collection that may collect significantly more particles than
popular exhaled breath condensate collection methods. The
improved collection efficiency gained through use of filters may
enable collection of sufficient material to result in measurement of
cytokines at levels above current assay detection limits, ultimately
leading to more reliable and repeatable assay data.
Our results also highlight the need to evaluate handling and
storage of cytokines to minimize degradation of samples when
developing methods for cytokine measurement. We observed a
potential increase in degradation of proteins in samples stored as
extracts at either 220uCo r280uC, a finding that concurs with
other recent work in this area. This may suggest that filter samples
containing cytokines should not be stored as concentrated extracts,
but as dry samples on filters at 220uCo r280uC until ready for
assay. Additional studies to confirm the validity of our finding and
are necessary to determine optimal storage of cytokine-containing
samples. Our findings provide the foundation for a potential new
technique to detect and measure cytokines and other non-volatile
pulmonary inflammatory biomarkers in human exhaled breath
samples.
Figure 6. Schematic diagram of single-pass aerosol chamber with HEART nebulizer. Single-pass aerosol chamber set up used for
nebulization and collection of aerosolized human cytokines. 2010-The MITRE Corporation Approved for Public Release: 10–1260. Distribution
Unlimited.
doi:10.1371/journal.pone.0035814.g006
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Overview
A single-pass aerosol chamber with biosafety hood for
nebulization of cytokine solutions was set up as shown in
Figure 6. Briefly, cytokine aerosols were generated with a HEART
nebulizer and dried while traveling through approximately 70
inches (1.78 m) of duct until reaching the sampling ports. A high
protein concentration in the nebulizer simulated respiratory lining
fluid source of respiratory droplets. Sampling ports used in the
chamber were designed to allow for isokinetic sampling of aerosols.
Three separate experiments were conducted using this system
evaluating a variety of factors influencing the collection, handling
and storage of human cytokine aerosols and are summarized in
Figure 7.
Initial Setup, Calibration and Evaluation of Aerosol
Generation and Collection System
A High-Output Extended Aerosol Respiratory Therapy
(HEART, Westmed Inc., Tucson, AZ) nebulizer was used for
nebulization of a mixed cytokine solution at 68.9 kPa based on
previous work demonstrating successful aerosol generation at this
pressure. The nebulizing solution contained 100 mL of 1X
Phosphate-Buffered Saline (PBS, Sigma-Aldrich, St. Louis, MO),
1% Bovine Serum Albumin (BSA; Sigma-Aldrich, St. Louis, MO)
and 0.01% (v/v) Tween-20 (Tween buffer; Polyethylene glycol
sorbitan monolaurate; Sigma-Aldrich, St. Louis, MO. The output
rate of the HEART nebulizer at 68.9 kPa was characterized for
stability over 30 mins by weighing the solution at 0, 10, 20 and 30
minutes and calculating amount of solution removed from the
nebulizer (Figure 7, Figure S21). The mean output rate of the
HEART nebulizer over 30 minutes was 0.32 g/min (Figure S21,
SD=0.06 g/min).
The centerline velocity of the 8 in duct of the aerosol chamber
was measured and recorded. The velocity profile for an 8 in duct
of the aerosol chamber was performed taken from a traverse of 10-
point measurements as described in the Pitot Traverse Method for
Round Pipe (ACGIH, Industrial Ventilation 23rd Ed.) from which
an average velocity was calculated (Figure 7). The centerline
velocity associated with the average velocity of the chamber
calculated from the pitot traverse was then used as a reference
value for setting the chamber flow rate. Measured centerline
velocity was 57 F/min (17.4 m/min). Calculated average velocity
was 53.6 F/min (16.3 m/min) which differed 6% from measured
centerline velocity.
Vacuum pumps used with each sampling device (Figure 7) were
calibrated using a rotometer (Part Number FM044040, Cole-
Parmer, Vernon Hills, IL) which was first calibrated by a soap
flow-meter (Gilibrator, Part Number D800285, Gillian Instrument
Corp., West Caldwell, NJ). Pumps were evaluated for flow stability
for 30 minutes. Mean % change in vacuum pump flow rate was
2.4% (SD = 1.1%, min = 0.7%, max = 3.9%).
Figure 7. Summary of experiments and methods.
doi:10.1371/journal.pone.0035814.g007
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All samples were assayed using a high sensitivity human
cytokine LINCOplex Kits (Millipore, Billerica, MA) according to
the manufacturer’s instructions and analyzed using a Luminex 200
IS System (Luminex Corporation, Austin, TX). All samples and
cytokine standards were assayed in a solution of 1X PBS/1%
BSA/0.01% Tween-20. Cytokine concentrations (pg/mL) for all
experiments were calculated using Upstate Beadview (Temecula,
CA) software.
Units of Measurement
Concentrations of prepared cytokine solutions are described
in pg/mL. Airborne concentrations of cytokines are reported in
pg/m
3 air and provide a useful context for interpretation of
sampler collection efficiencies and reported assay measurements.
All other reported results are presented in total mass (pg) of
cytokine measured or collected by the sampling device.
Experiment 1: Estimation of Aerosolized Cytokine
Concentrations and Comparison of Aerosol Sampler
Collection Efficiency
A HEART nebulizer was employed to generate aerosols of six
human cytokines (IFN-gamma, IL-1 beta, IL-7, IL-8, IL-13, and
TNF-alpha; Millipore, St. Charles, MO) at 68.9 kPa from a
100 mL solution containing 50 pg/ml of each cytokine in 1X PBS
buffer prepared as described previously. Samples were removed
from the nebulizer solution using a syringe attached to a separate
sampling port located on the top of the HEART nebulizer that did
not interfere with nebulization.
Using Luminex assay data, concentrations of each cytokine
present in the HEART nebulizer solution before and after
nebulization were determined. Estimations of expected airborne
cytokine concentrations (Figure 7) were then calculated as follows:
CA~
CN,0VN,0{CN,tVN,t
VA
t ð1Þ
Where CA is the expected airborne cytokine concentration (pg/
m
3), CN,0 is the pre-nebulization cytokine concentration in the
nebulizer (pg/mL) and CN,t is the post nebulization concentration
(pg/mL), VN,0 is the volume of fluid in the nebulizer pre-
nebulization (mL) and VN,t is the volume post-nebulization (mL),
and VA-dot is the average air flow in the chamber(m
3/min) and t is
the duration of the experiment (min).
Mean airborne cytokine concentrations and 95% CI values for
each cytokine collected in the study were calculated.
From the same aerosol generated for the purpose of estimating
cytokine aerosol concentrations, we tested the collection efficiency
of the BioSamplerH (SKC Inc., Eighty Four, PA); the Omni-
3000
TM (Sceptor Industries, Kansas City, MO); and Teflo
TM 2.0
micron TeflonH filters (Pall Corporation, East Hills, NY) housed in
37 mm polypropylene cassettes using the same chamber set up
(Figures 6 and 7). Samples were concurrently collected for
15 minutes. Tunnel flow rate was 566 L/min and sampler flow
rates for the BioSamplerH, Omni-3000 and filter cassettes were
12.5 L/min, 252 L/min, and 28.3 L/min, respectively.
Aliquots of 1 mL were taken directly from the BioSamplerH and
Omni-3000
TM using a syringe. Filter washes were performed
immediately after collection as follows. First, filters were cut with
scissors around perimeter by making a series of notches in the
polypropylene support ring. Next, each filter was placed in 1.5 mL
polypropylene centrifuge tubes and rinsed by vortexing in 1 mL of
1X PBS/1% BSA/0.01% Tween-20 solution. All samples were
then concentrated 10-fold using a centrifugal rotary evaporator.
Cytokine concentrations were normalized for air volume, liquid
collection volume, and filter extraction volume. The measured
concentration of cytokine collected by each sampling device was
then calculated as described below in Equation 2.Equation 2.
CD~
MD
VDt
ð2Þ
Where CD is the measured concentration of cytokine collected by
the sampling device, MD is the average total mass of cytokine
collected by the sampling device based on reported immunoassay
concentrations, VD-dot is the air flow to the sampling device, and t
is the sampling time.
Mean collection efficiencies for each collection device were
calculated by dividing the measured cytokine concentrations
collected by each sampling device (Equation 2) by the estimated
airborne cytokine concentration (Equation 1) as summarized
below in Equation 3:
EC~
CD
CA
ð3Þ
Where EC is the collection efficiency of the device, CD is the
measured concentration of cytokine collected by the sampling
device, and CA is the estimated airborne cytokine concentration
calculated as described in Equation 1.
Mean collection efficiencies and 95% CI values for all six
cytokines and mean collection efficiencies for individual cytokines
using each device were calculated.
Experiment 2: Cytokine Stability, Use of Filter
Centrifugation Concentration and Effect of Sampling
Time and Cytokine Concentrations on Assay
Repeatability
Potential degradation of cytokines during nebulization was
evaluated (Figure 7) by calculating the total amount of cytokine
present in the nebulization solution at 10 minute intervals from 0
to 30 minutes. For this experiment, a HEART nebulizer generated
aerosols of a solution of six human cytokines containing 25 pg/ml
of each cytokine in 1X PBS buffer prepared as described in
Experiment 1. Samples were removed from the nebulizer solution
at the time points listed above using a syringe and then assayed by
multiplex immunoassay.
Preliminary experiments indicated approximately 50% sample
loss due to use of the rotary centrifugal evaporator for
concentration of filter extracts. Thus, use of Amicon Ultra-4
3000 MWCO centrifugal filter concentrators (Millipore, Billerica,
MA) was evaluated for 10-fold concentration of solutions
containing human cytokines (Figure 7). For this experiment,
cytokine recovery from solution was determined by spike-recovery
experiments using human cytokine standards at a concentration of
10 pg/mL in 1X PBS buffer prepared as described in Exper-
iment 1. Passivation or pre-treatment of the centrifugal filter
concentrators with a solution of 1% powdered milk in 1X PBS, as
suggested by the manufacturer, was also performed for compar-
ison to untreated filters to assess whether passivation yielded
improved recovery of cytokines. Additionally, the mean collection
efficiency of filter samples generated in Experiment 2, extracted
and then concentrated using centrifugal filter concentrators was
calculated as described in Experiment 1 (Equations 1–3) and
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using rotary centrifugal evaporation in Experiment 1.
Results from Experiment 1 indicated collection of aerosolized
cytokines in the pg/m
3 range which when assayed by multiplex
immunoassay included reported levels near or slightly above the
manufacturer’s reported minimum detectable concentrations
(MinDC) which range from 0.01 pg/mL to 0.48 pg/mL and vary
by cytokine. According to the assay manufacturer, MinDC is
calculated using StatLIAH Immunoassay Analysis Software
(Brendan Technologies Inc., Carlsbad, CA) by mathematically
determining what the empirical value for MinDC would be if an
infinite number of standard concentrations were run in an
assay under identical conditions. Min DC values for IL-1 beta,
IL-7, IL-8, IL-13, IFN-gamma, and TNF-alpha were 0.06, 0.12,
0.11, 0.48, 0.29, and 0.05 pg/mL, respectively.
To evaluate repeatability of assay measurements at the
manufacturer’s MinDC range for the multiplex immunoassay as
well as to investigate the effect of increasing sampling times of
aerosols containing cytokines present in the pg/m
3 range
(Figure 7), we prepared solutions of six human cytokine standards
as described in Experiment 1, at three different concentrations:
25 pg/mL; 10 pg/mL; and 1 pg/mL. Sampling times and starting
concentrations were selected based on the goal of achieving
collected cytokine amounts below, near, and one to two orders of
magnitude above the manufacturer’s reported MinDC of the
multiplex immunoassay.
Assumptions regarding sample loss and recovery were made
based on earlier experiments and used in calculations to determine
optimal cytokine concentrations and sampling times to produce
the desired range of cytokine concentrations in the concentrated
filter extracts.
After a chamber stabilization period of 15 minutes, solutions
containing 25 pg/mL, 10 pg/mL, or 1 pg/mL were nebulized
and delivered into a single-pass aerosol chamber and collected by
Teflo
TM TeflonH filter sampling cassettes. Duplicate filter samples
were collected for each concentration of cytokine standards at
each of three sampling times: 10; 20; and 30 minutes. Additionally,
duplicate filter samples of nebulized 1X PBS/1% BSA/0.01%
Tween-20 solution containing no cytokine standards were
collected at 10, 20 and 30 minutes to serve as negative control
samples. Two separate trials were performed for each concentra-
tion and sampling time. One laboratory blank sample which
received no air exposure was collected for each of the two trials.
Volume of total nebulizer solution was recorded and aliquots of
nebulizer solution were taken at 0 minutes and 30 minutes after
the start of nebulization.
All filter washes were performed as described in Experiment 1.
However, Amicon Ultra-4 3000 MWCO centrifugal filter
concentrators (Millipore, Billerica, MA) were employed in this
experiment for 10-fold concentration of all filter washes and 1 mL
nebulizer solution aliquots.
All samples were assayed by multiplex immunoassay and
analyzed to determine cytokine levels (pg/mL) present in each
sample. Values for samples with cytokine levels below the lowest
standard of the assay (0.03 pg/mL) were calculated using linear
regression methods of the four lowest data points of the standard
curve for each cytokine. First, mean and standard deviation values
were calculated for the median fluorescent intensity values of two
sample matrix blanks assayed in duplicate (4 sample matrix blank
intensity values/cytokine). Next, a limit of detection (LOD) value
in intensity units was calculated for each cytokine by calculating
the sum of the mean intensity value of the sample blank plus 3 SDs
of the mean. The four lowest standards of the assay that were
equal to or greater than this calculated intensity-based LOD value
were then selected for inclusion in the linear regression analysis.
Estimations of each sample concentration (pg/mL) measuring
below the lowest standard of the assay were then made by using
the linear regression equation calculated for each cytokine to
determine sample concentration (pg/mL) using sample median
fluorescent intensity values as input values in the regression
equation.
Experiment 3: Effect of Storage Conditions
In order to evaluate handling and storage of human cytokine
aerosols collected using filters, we compared storage of filters
containing dried samples and concentrated filter extracts at two
different temperatures to that of samples assayed immediately after
collection (Figure 7). For this experiment, thirteen human cytokine
standards (GM-CSF, IFN-gamma, IL-1 beta, IL-10, IL-12(p70),
IL-13, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-alpha,
Millipore, Billerica, MA) were prepared in solution as described
in Experiment 1 at a concentration of 50 pg/mL and added to the
HEART nebulizer. The solution was nebulized into a single-pass
aerosol chamber connected to Teflo
TM TeflonH filter sampling
cassettes. A total of six replicate filter samples were collected for
each of five storage conditions utilizing a 20 minute sampling time:
1. No storage; wash, concentrate and assay immediately after
collection.
2. Store at 220uC for 2 weeks, then wash, concentrate and assay.
3. Store at 280uC for 2 weeks, then wash, concentrate and assay.
4. Wash and concentrate. Store at 220uC for 2 weeks, then assay.
5. Wash and concentrate. Store at 280uC for 2 weeks, then assay.
A total of 30 filters were collected in the study (5 conditions, 6
replicate filters/condition) and assayed in duplicate for a total of
60 measurements. Location of each filter collected for each
condition was randomized across all sample collection runs. Five
filter blanks (one for each storage condition) were collected
receiving airflow containing 1X PBS/1% BSA/0.01% Tween-20
buffer only and served as negative control samples. Additionally,
five laboratory blank filters that received no airflow were collected.
All filter washes were performed as described previously and
concentrated 10-fold using Amicon Ultra-4 3000 MWCO
centrifugal filter concentrators. Values for samples displaying
cytokine measurements below the lowest standard of the assay
were calculated as described in Experiment 2.
Statistical Analyses
A Kruskal-Wallis (non-parametric) analysis of variance test was
used to determine if differences between sampling devices
compared in Experiment 1 were significant. If the analysis of
variance test indicated significant differences among the sampling
devices and data were approximately Gaussian, student’s t-tests
were performed to pairwise compare mean collection efficiencies
of samplers.
In Experiment 2, Tukey box plots were generated to evaluate
cytokine degradation due to nebulization and significant differ-
ences in cytokine levels over 30 minutes of nebulization were
determined using a Kruskal-Wallis analysis of variance test. Mean
cytokine amounts (pg, 95% CI) for all six cytokines for each
sampling time and concentration were plotted and compared
using a Kruskal- Wallis analysis of variance test to test for
significant differences. Additionally, the variability of the cytokine
measurements made below, near and one to two orders of
magnitude above the MinDC using our method was assessed.
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performed to determine any cytokine specific effects of two
different storage temperatures (220uC vs. 280uC) on samples
stored as filters and as concentrated filter extracts as compared to
samples assayed immediately after collection. Mean cytokine levels
(pg) for each storage condition were plotted using Tukey box-plots
and compared using a Kruskal- Wallis analysis of variance test to
test for significant differences among storage conditions globally
across all thirteen cytokines. Student’s t-tests (approximately
Gaussian data) were used to compare the four storage conditions
to the control condition (no storage).
All statistical analyses were performed using GraphPad Prism
version 5.00 for Windows, (GraphPad Software, San Diego, CA).
Supporting Information
Figure S1 Stability of cytokines during nebulization.
Tukey box plot of mean levels (pg/mL) for all six cytokines over 30
minutes of nebulization. Differences in mean cytokine amounts
across sampling times up to 30 minutes are not significant (Kruskal-
Wallis, P.0.05), (N=12, 2 samples for each of 6 cytokines).
(TIF)
Figure S2 Effect of sampling time and initial starting
concentration on IFN-gamma collection. Measured levels of
IFN-gamma (pg) collected using Teflon filters in aerosol chamber
for 10, 20 and 30 minutes at starting concentrations of 1, 10 and
25 pg/mL. 95% CI bars are shown (N=8, 4 filters assayed in
duplicate).
(TIF)
Figure S3 Effect of sampling time and initial starting
concentration on IL-1 beta collection. Measured levels of IL-
1 beta (pg) collected using Teflon filters in aerosol chamber for 10,
20 and 30 minutes at starting concentrations of 1, 10 and 25 pg/
mL. 95% CI bars are shown (N=8, 4 filters assayed in duplicate).
(TIF)
Figure S4 Effect of sampling time and initial starting
concentration on IL-13 collection. Measured levels of IL-13
(pg) collected using Teflon filters in aerosol chamber for 10, 20 and
30 minutes at starting concentrations of 1, 10 and 25 pg/mL. 95%
CI bars are shown (N=8, 4 filters assayed in duplicate).
(TIF)
Figure S5 Effect of sampling time and initial starting
concentration on IL-7 collection. Measured levels of IL-7 (pg)
collected using Teflon filters in aerosol chamber for 10, 20 and 30
minutes at starting concentrations of 1, 10 and 25 pg/mL. 95% CI
bars are shown (N=8, 4 filters assayed in duplicate).
(TIF)
Figure S6 Effect of sampling time and initial starting
concentration on IL-8 collection. Measured levels of IL-8 (pg)
collected using Teflon filters in aerosol chamber for 10, 20 and 30
minutes at starting concentrations of 1, 10 and 25 pg/mL. 95% CI
bars are shown (N=8, 4 filters assayed in duplicate).
(TIF)
Figure S7 Effect of sampling time and initial starting
concentration on TNF-alpha collection. Measured levels of
TNF-alpha (pg) collected using Teflon filters in aerosol chamber for
10,20and30minutes atstarting concentrationsof1,10and 25 pg/
mL. 95% CI bars are shown (N=8, 4 filters assayed in duplicate).
(TIF)
Figure S8 Effect of storage condition on mean cytokine
levels for GM-CSF. Tukey box plots showing effect of five
different storage conditions on recovered amounts (pg) of GM-
CSF. (N=12, 6 filters assayed in duplicate).
(TIF)
Figure S9 Effect of storage condition on mean cytokine
levels for IFN-gamma. Tukey box plots showing effect of five
different storage conditions on recovered amounts (pg) of IFN-
gamma. (N=12, 6 filters assayed in duplicate).
(TIF)
Figure S10 Effect of storage condition on mean cytokine
levels for IL-1 beta. Tukey box plots showing effect of five
different storage conditions on recovered amounts (pg) of IL-1
beta. (N=12, 6 filters assayed in duplicate).
(TIF)
Figure S11 Effect of storage condition on mean cytokine
levels for IL-10. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-10. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S12 Effect of storage condition on mean cytokine
levels for IL-12p70. Tukey box plots showing effect of five
different storage conditions on recovered amounts (pg) of IL-
12p70. (N=12, 6 filters assayed in duplicate).
(TIF)
Figure S13 Effect of storage condition on mean cytokine
levels for IL-13. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-13. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S14 Effect of storage condition on mean cytokine
levels for IL-2. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-2. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S15 Effect of storage condition on mean cytokine
levels for IL-4. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-4. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S16 Effect of storage condition on mean cytokine
levels for IL-5. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-5. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S17 Effect of storage condition on mean cytokine
levels for IL-6. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-6. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S18 Effect of storage condition on mean cytokine
levels for IL-7. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-7. (N=12, 6
filters assayed in duplicate).
(TIF)
Figure S19 Effect of storage condition on mean cytokine
levels for IL-8. Tukey box plots showing effect of five different
storage conditions on recovered amounts (pg) of IL-8. (N=12, 6
filters assayed in duplicate).
(TIF)
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levels for TNF-alpha. Tukey box plots showing effect of five
different storage conditions on recovered amounts (pg) of TNF-
alpha. (N=12, 6 filters assayed in duplicate).
(TIF)
Figure S21 HEART nebulizer output rate. Output rate of
HEART Nebulizer over 30 minutes at 10 psi with 100 mL
starting volume of 1X Phosphate Buffered Saline (PBS) solution
containing 1% Bovine Serum Albumin (BSA) and 0.01% Tween-
20.
(TIF)
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